Io Therapeutics, Inc., presented data from studies of IRX4204
资讯
2024-07-10
Io Therapeutics, Inc., presented data from studies of IRX4204, the company's phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting it...